Ashley Hall - Dec 9, 2022 Form 4 Insider Report for Reneo Pharmaceuticals, Inc. (RPHM)

Role
Chief Development Officer
Signature
/s/ Jennifer P. Lam, Attorney-in-Fact
Stock symbol
RPHM
Transactions as of
Dec 9, 2022
Transactions value $
$0
Form type
4
Date filed
12/13/2022, 05:11 PM
Previous filing
Nov 15, 2021
Next filing
Aug 29, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding RPHM Common Stock 35.6K Dec 9, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RPHM Stock option (right to buy) Award $0 +125K $0.00 125K Dec 9, 2022 Common Stock 125K $1.80 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 1,600 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan (the "Plan") on June 8, 2022 and 4,000 shares acquired under the Plan on December 8, 2022.
F2 The shares vest in a series of 16 equal quarterly installments measured from December 9, 2022 subject to Reporting Person's Continuous Service (as defined in the Issuer's 2021 Equity Incentive Plan) as of each such vesting date.